NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Because that was 2023 ex, and this is 2024. For the past few years, the MHRA was too understaffed to review all the new clinical trial applications and marketing applications within their established timelines, so last year the MHRA received extra funding, hired and trained new assessors, and streamlined processes to clear their backlog, and is attempting to meet their established timelines again in 2024.

The MHRA prioritizes some applications over others like generics or other low-priority drugs, so some applications took longer than others, and the applications that you refer to were assessed before new assessors were on the job and clearing backlogs.

I think it’s highly likely that Northwest Bio’s application will receive priority review, since it treats a serious, deadly disease, and is a significant improvement over the current treatment. Plus the MHRA will want to tout its accomplishment for being the first to rapidly approve this innovative advanced therapy, and get it to desperate patients.

I know this is going to be difficult for you and those in your pack to accept, but we ALL know approval is coming. (yes even you) The only thing that’s really up for debate is WHEN, so enjoy this silly argument while you can.